Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 861

Results For "IT"

11231 News Found

India achieves 15,000+ transplants in a year
News | February 20, 2023

India achieves 15,000+ transplants in a year

There is a fast resurgence in the transplant activities post COVID


Briefs: Neuland Laboratories, Cipla and Zydus
Drug Approval | February 20, 2023

Briefs: Neuland Laboratories, Cipla and Zydus

Cipla has received 8 inspectional observations in Form 483


Pfizer announces Talzenna and Xtandi combination data from phase 3 study
News | February 18, 2023

Pfizer announces Talzenna and Xtandi combination data from phase 3 study

Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI


Asahi Kasei completes construction of microcrystalline cellulose plant
News | February 18, 2023

Asahi Kasei completes construction of microcrystalline cellulose plant

With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC


Dr. Mandaviya hails eSanjeevani milestone of providing telemedicine services to 10 Cr patients
News | February 18, 2023

Dr. Mandaviya hails eSanjeevani milestone of providing telemedicine services to 10 Cr patients

eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation


Zydus receives final approval from USFDA for Sirolimus Tablets, 1 mg and 2 mg
Drug Approval | February 18, 2023

Zydus receives final approval from USFDA for Sirolimus Tablets, 1 mg and 2 mg

Sirolimus Tablets had annual sales of USD 69 million in the United States (IQVIA MAT Dec. 2022)


Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing
Drug Approval | February 18, 2023

Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing

Themis will market this drug with the brand name REMITHEM.


Merck and AstraZeneca present final results from Phase 3 PROpel Trial
Drug Approval | February 18, 2023

Merck and AstraZeneca present final results from Phase 3 PROpel Trial

Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival


Garuda Aerospace and Narayana Health join hands to transport biomedical supplies using drone
News | February 18, 2023

Garuda Aerospace and Narayana Health join hands to transport biomedical supplies using drone

The partnership is announced at Aero India 2023, Bangalore


Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg
Drug Approval | February 18, 2023

Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg

According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million